Evaluating the safety and efficacy of recombinant human thrombopoietin among severe sepsis patients with thrombocytopenia: study protocol for a randomized controlled trial by Qin Wu et al.
TRIALS
Wu et al. Trials  (2015) 16:220 
DOI 10.1186/s13063-015-0746-6STUDY PROTOCOL Open AccessEvaluating the safety and efficacy of recombinant
human thrombopoietin among severe sepsis
patients with thrombocytopenia: study protocol
for a randomized controlled trial
Qin Wu1, Jianan Ren1*, Gefei Wang1, Guosheng Gu1, Dong Hu1, Song Liu1, Gunawei Li1, Jun Chen1, Ranran Li1,
Zhiwu Hong1, Huajian Ren1, Xiuwen Wu1, Yuan Li1, Min Yao2, Yunzhao Zhao1 and Jieshou Li1Abstract
Background: Sepsis is still a major health problem that causes high mortality in all populations. Organ dysfunction
including sepsis-associated thrombocytopenia is prevalent among sepsis patients, resulting in increasing mortality
rates. Considering the clinical role of platelets, thrombocytopenia in sepsis has led to a large spend in research activity
and clinical trials in this area, yet there is no consensus upon which treatment should be administered. As a result,
platelet transfusion is often indicated to resolve low platelet counts, leading to an increasing risk of the multiple risks
transfusion brings, such as infectious or immune system complications. Given the role of thrombopoietin in stimulating
proliferation and differentiation of megakaryocytes, our previous study investigated the potential benefits of recombinant
human thrombopoietin in severe sepsis patients with thrombocytopenia. However, there are several limitations in the
study, which may have led to bias in our conclusion. Thus, we are conducting this study in order to evaluate the safety
and efficacy of recombinant human thrombopoietin in a large, varied population.
Methods/Design: The study is designed as a randomized, open-label, placebo-controlled, multi-center study in tertiary
academic centers for evaluating the safety and efficacy of recombinant human thrombopoietin over placebo. An
established total of 708 patients with sepsis and thrombocytopenia will undergo prospective random assignment
to recombinant human thrombopoietin or placebo (a 1:1 ratio). The primary endpoint is 7-day all-cause mortality
and 28-day all-cause mortality.
Discussion: To our knowledge, this is the first study to evaluate the safety and efficacy of recombinant human
thrombopoietin among severe sepsis patients with thrombocytopenia in a varied population. With our study, the
level of evidence for the treatment of these patients will be significantly raised.
Trial registration: ClinicalTrials.gov: NCT02094248. Registration date: 23 March 2014.
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Defined as a systemic deleterious host response to infec-
tion, sepsis is still a major healthcare problem around
the world [1]. It is characterized by the cardinal signs of
inflammation, including vasodilation, increased microvascu-
lar permeability and cell dysfunctions [2].
Despite their small size and anucleate status, platelets
have diverse roles in vascular biology during sepsis. Not
only are platelets the cellular mediator of thrombosis,
but platelets are also immune cells that initiate and ac-
celerate many vascular inflammatory conditions [3]. Due
to a response to a systemic bacterial infection, continued
platelet activation in sepsis patients is prevalent, leading
to sepsis-associated thrombocytopenia [4]. Researches
have suggested that the declining platelet counts (PCs)
are associated with mortalities among sepsis patients
caused by various diseases, indicating the importance of
recovering from thrombocytopenia during sepsis [5, 6].
To date, evidence-based treatment strategies for
sepsis-associated thrombocytopenia have not yet reached
consensus for clinical practice. The management of
thrombocytopenia remains a challenge. In the guide-
lines of surviving sepsis, platelet transfusion is advised
to be administered when PCs are below 10 × 109/L in
the absence of apparent bleeding or below 20 × 109/L
if the patient has a significant risk of bleeding [1]. Studies
have reported that early recovery from thrombocytopenia
helps to prevent coagulopathy and decreases the mortality
rate [7, 8]. Taking all of the above into account, more ag-
gressive approaches to reverse the pathophysiological
process of thrombocytopenia in severe sepsis are indeed
required.
Several growth factors are involved in the process of
platelet generation. Among them, thrombopoietin, which
has been identified for its ability to stimulate prolifera-
tion and differentiation of megakaryocytes, has been
identified [9]. Recent study has demonstrated the role of
thrombopoietin as an effective stimulus for promoting
hematopoietic stem cells when administered before
radiotherapy to minimize hematopoietic stem cell injury
and mutagenesis in mice, indicating the varied potentials
of this factor [10].
Our previous study demonstrated that administration
of recombinant human thrombopoietin (rhTPO) with
conventional medical therapies could significantly improve
the PCs in severe sepsis patients with thrombocytopenia
and effectively reduce the platelet transfusion possibility
[11]. We also observed significantly different mortality rates
between the intervention group and the control group.
This previous study is a single-center non-randomized pro-
spective study. There are several limitations in the study,
which may have led to bias in our conclusion. Thus, we
have designed a clinical study that will evaluate the safety
and efficacy of rhTPO in a large, varied population.Methods
Objectives
The objective of this study is to determine the safety
profile and efficacy profile of rhTPO in a large, varied se-
vere sepsis population.
Study design
The study is designed as a randomized, open-label,
placebo-controlled, multi-center study in 17 tertiary aca-
demic medical centers. The sites that are participating in
this study are medical, surgical or emergency ICUs. Pa-
tient enrollment is expected to last up to 18 months.
The end of the study is defined by the last follow-up of
the last enrolled patient. The trial is registered at clini-
caltrials.gov (NCT02094248).
Qualified patients will be randomized into either of
the two groups: the intervention group and the control
group. Both groups receive standard care and will re-
ceive appropriate medical support based on guidelines
issued by the surviving sepsis campaign [1].
The intervention group will receive administration of
rhTPO (TPIAO™, Shenyang Sunshine Pharmaceutical
Company Limited (SUNSHINE), Shenyang, China). The
rhTPO will be subcutaneously injected in the interven-
tion group after randomization. The dose is 15,000 U
per day. The subcutaneous injection will be terminated
when PCs are increased by 50 × 109/L for 2 consecutive
days compared with PCs at baseline. The duration of
rhTPO will be 7 days. Time from randomization to ad-
ministration of rhTPO will be within 24 hours.
Patients in the control group will receive the equal
amount of normal saline, which will be subcutaneously
injected as a placebo. The normal amount of saline is 1
ml per day for the initial stage and the maintenance
stage. The subcutaneous injection will be terminated
after 7 days. Time from randomization to administration
of placebo will also be within 24 h.
Recruitment
A principle investigator, assisted by a well-trained study
coordinator in each participating center, will identify po-
tentially eligible patients based on the eligibility criteria.
And they, in collaboration with the treating physician,
will confirm patient eligibility for the trial. The study co-
ordinator will then obtain written informed consent
from the patient. Patients will be consecutively enrolled
at each of the participating centers whenever a study co-
ordinator is available for enrollment. Consent will be ob-
tained from participating clinicians before or at the time
of patient consent.
Eligibility and exclusion criteria
The detailed eligibility and exclusion criteria are listed in
Additional file 1.
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Eligible, non-randomized patients will be those who
meet all inclusion criteria but are not included in the
trial because of refusal of consent or inability to obtain
consent within 12 h of the patient meeting the eligibility
criteria. For these patients, we will collect data of platelets
at baseline and at the time of eligibility, severity of illness
at the time of eligibility, and their vital status in the ICU
and at hospital discharge. The collection of these data will
enable comparisons with randomized patients to assess
threats to the generalizability of the trial results.
Screening
Given the dynamic nature of the inclusion criteria, research
coordinators will screen patients in each study center for
eligibility once a day, either the morning or afternoon. Re-
search coordinators will discuss all patients who meet the
inclusion criteria, without an exclusion criterion, with the
attending intensivist to confirm the inclusion.
Randomization
Patients will be randomized after informed consent is
obtained and it is confirmed that all inclusion and no
exclusion criteria are met, prior to the patient-clinician
discussion of treatment options and patient risk. Alloca-
tion will be based on a 1:1 ratio between the intervention
and control groups. The allocation sequence will be gener-
ated by utilizing the ResMan Research Manager central
randomization clinical trial management public platform
(http://www.medresman.org/). The randomization will be
stratified by study site. On the day of inclusion, investiga-
tors will log information into the web database using user
identifications and passwords to obtain the randomization
numbers and allocated groups for the eligible patients.
Both investigators and participants will be aware of the
allocations.
Blinding
No blinding will take place in this study. Eligible patients
who have given consent will be randomized into either
of the two groups.
Study flowchart
The study flowchart is listed in Additional file 2.
Outcome measurements
Primary outcome
The primary outcome of this study is the 7-day all-cause
mortality and 28-day all-cause mortality.
Secondary outcomes
The secondary outcomes of this study will include the
following:1. The number of participants who survive
thrombocytopenia at the seventh day after
randomization.
2. The total amount of platelets transfused into
participants during the observational period.
3. The time to recovery to a normal platelet level.
4. The occurrence of bleeding events.
In this study, the normal platelet level is defined as
PCs not less than 100 × 109/L. Time to recovery to a
normal platelet level is calculated from the date of
randomization to the date when PCs >>100 × 109/L.
Data management
A case report form (CRF) is used for each patient to col-
lect the data. Assessments are made at the screening
period, inclusion (D0) and on days 1 to 7. Assessments
include sepsis-related organ failure assessment, monitor-
ing (catheter, tubes and drains, mechanical ventilation
procedures), laboratory tests (hematology, biochemistry,
urinalysis, pregnancy test at inclusion only), and micro-
biology (blood cultures, mycology). Data on adverse
events, compliance and concomitant treatments are col-
lected at each visit. We will determine vital status among
survivors at 28 days following randomization through
chart review and direct contact with patients if necessary.
Participants will be evaluated every day till the seventh
day after randomization. Physicians and research nurses
who are not involved in the patients’ care will assess the
outcome.
All documents collected in this study will be stored
safely in confidential conditions. On all study-specific
documents, other than the signed consent, the participant
will be referred to by the study participant number/code,
not by name. Study documentation will be archived for a
period of 5 years after the study.
Adverse events
All adverse events will be recorded and closely moni-
tored until resolution or stabilization or until it has been
shown that the study treatment is not the cause of the
event. The chief investigator will be informed immedi-
ately of any serious adverse events and will determine
(in cooperation with the treating medical practitioners)
the seriousness and causality of these events.
All treatment-related serious adverse events will be re-
corded and reported to the research Ethics Committee
as part of the report. Unexpected serious adverse events
will be reported to the research Ethics Committee within
the relevant time frames. The chief investigator will be
responsible for all adverse event reporting. All site staff
will be appropriately trained in the procedures to follow
and the forms to use during the study protocol prior to
study initiation. Regular central monitoring for all studies
Wu et al. Trials  (2015) 16:220 Page 4 of 5and site monitoring, as determined by the trial-specific
risk assessment, will be used to ensure that all adverse
events are identified and acted on appropriately.
Statistical analysis
Sample size and statistical analysis
The all-cause mortality of sepsis varies in different patient
populations. The mortality of 28-day ranges from 20.8% to
61% but no reliable 7-day mortality has been reported to
our knowledge [12, 13]. Using the 28-day mortality in our
center, we assumed that the 7-day mortality is 40%. Our
sample size was calculated to detect a 10% difference in
mortality at day 7 between the two groups with a two-
tailed test, a significance level (alpha) of 5% and a power
of 80%. We plan to include a total of 708 subjects.
Type of analysis
We will utilize an intention-to-treat approach to examine
differences in the mortality in the two groups in the pri-
mary analysis by the Pearson χ2 test. Safety parameters
and secondary efficacy parameters will be analyzed using
the Pearson χ2 test and logistic regression (if necessary).
Cox proportional hazards models and the Kaplan-Meier
method will also be applied. Adverse events will be tabu-
lated according to randomized group assignment and the
proportions will be compared using Fisher’s exact test.
Ethics
Declaration of Helsinki
The research team will ensure that this study is con-
ducted in accordance with the principles of the Declar-
ation of Helsinki [14].
Ethics committee and regulatory approval
The trial will also be conducted in accordance with the
national ethics review for biomedical research involving
humans (Trial) [15]; and international ethical guidelines
for biomedical research involving human subjects [16].
The protocol, informed consent form, participant in-
formation sheet, any further patient documents and any
proposed advertising material were submitted to the In-
stitutional Review Board (IRB) of the Ethics Committee
of Jinling Hospital for written approval. The research
team has obtained approval from the Ethics Committee of
Jinling Hospital for all substantial amendments to the ori-
ginal approved documents (approval number 2014SY-079).
Protocol amendments
Any modifications to the protocol that may impact on
the conduct of the study, the potential benefit of the pa-
tient or may affect patient safety, including changes of
study objectives, study design, patient population, sample
sizes, study procedures, or significant administrative as-
pects will require a formal amendment to the protocol.Such amendments will be agreed upon by the sponsor,
and approved by the Ethics Committee prior to imple-
mentation and notified to the health authorities in accord-
ance with local regulations.
Administrative changes of the protocol are minor cor-
rections and/or clarifications that have no effect on the
way the study is to be conducted. These administrative
changes will be agreed upon by the sponsor, and will be
documented in a memorandum. The Ethics Committee
may be notified of administrative changes.
Trial oversight
The oversight of this trial comprises three parts.
1. The Steering Committee. The committee will meet
monthly by teleconference to review and address
operational issues.
2. The Coordinating Center. The Department of
General Surgery, Jinling Hospital, Nanjing, China,
will serve as the central trial coordination and data
management center. This department will work
closely with the Steering Committee to coordinate
trial activities, and will be responsible for managing
trial sites, obtaining regulatory approvals, safety
reporting, maintaining and archiving trial
documentation, sourcing and distributing trial
materials, developing electronic CRFs, training trial
staff, performing data validation and monitoring
activities, performing statistical programming and
analysis, and providing results of analyses.
3. The Data and Safety Monitoring Board. The three
members of the IRB are comprised of experts in
statistics, critical care, and clinical research. The
board members will meet by teleconference every
month while the trial is actively recruiting. The
primary role of the board will be to monitor adverse
events among trial participants. The board will
assess whether these events are linked to




The investigators will be involved in reviewing drafts of
the manuscripts, abstracts, press releases, and any other
publications arising from the study. Authors will acknow-
ledge that the study was funded by the National Natural
Science Foundation of China (81270478). The key point of
this study design is summarized in Additional file 3.
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This study is designed as an open-label study and physio-
logical serum is used as a placebo. There is a possibility
that the positive effect of rhTPO just lies among the surgi-
cal patients. For medical septic patients (for example
pneumonia-derived sepsis), the role of rhTPO might be
different. Thus, a placebo group in which physiological
serum is administered could provide baseline data for the
whole population. Also, the placebo group could be used
to conduct a patient stratification analysis at the end of
the study. So this study is designed as an open-label study
and physiological serum is used as a placebo. The detailed
reviewer’s comments and the author’s reply can be found
in Additional file 4.
To our knowledge, this is the first study to evaluate
the safety and efficacy of rhTPO among severe sepsis pa-
tients with thrombocytopenia in a varied population.
With our study, the level of evidence for the treatment
of these patients will be significantly raised.Trial status
The study was conceived and designed in 2014. We are
now recruiting participants.Additional files
Additional file 1: Flowchart of this study. The study is divided into
three stages. Patients would be enrolled during the initial stage. After
randomization, patients would receive treatment during the treatment
visit stage. In addition, the follow-up stage would last until 28 days after
enrollment.
Additional file 2: Eligibility and exclusion criteria of this study.
Additional file 3: Study summary. The key message of this study
protocol is summarized in this table.
Additional file 4: The reviewer’s comments and the author’s reply.
We explain why this study is designed as an open-label study and
physiological serum is used as a placebo.Abbreviations
CRF: case report form; PCs: platelet counts; rhTPO: recombinant human
thrombopoietin.
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